OSE-127 (Effi-7), a license option agreement with Servier for the product’s development and commercialization
A 2-steps license option to develop OSE-127 (Effi-7) to enable the development of the product up to the completion of a phase 2 clinical trial planned in ulcerative colitis, an autoimmune bowel disease (Press release)
- OSE-127 is a monoclonal immunomodulatory antibody targeting the alpha chain of the interleukin-7 receptor (IL-7R-alpha or CD127 receptor). Effi-7 has an innovative mechanism of action: it blocks both the IL-7 and the internalization of the receptor, thus inducing a powerful antagonist effect on the pathogenic T lymphocytes involved in autoimmune diseases. This mechanism has been confirmed recently through multiple in vitro and in vivo studies.
- Currently in preclinical stage for ulcerative colitis, the development of OSE-127 will also be pursued until the clinical phase 2 as part of the EFFIMab (Scientific collaborations) consortium, led by OSE Immunotherapeutics and including the University Hospital of Nantes and INSERM.
New collaboration and license agreements on other programs will be considered with industry partners involved in activation or regulation immunology, and in therapeutic combinations of high clinical interest.